Updated Covid Jabs [Not] Working on New Variants

Not that they ever worked, but now even more so, if that is even possible.

Sep 12, 2023

BA 2.86 is being called variant under monitoring by WHO. BA 2.86 is said to be highly mutated and this particular strain has some new symptoms associated with it, says Dr Pavithra Venkatagopalan, corona-virologist and Covid awareness specialist at Rotary Club of Madras NextGen in a conversation with HT Digital.(Pixabay)

As we are eagerly anticipating our next updated, new-and-improved Covid Jab No. 7, to bring our immune system to the coveted up-to-date status, conflicting messages are pouring in as to the effectiveness of this new jab on the latest SARS-CoV-2 variants EG.5.1 and BA.2.86, the latter being the newest kid on the block.

As always, the CDC puts the best foot forward, “US CDC says existing antibodies can work against new COVID variant” (Sep. 8, 2023):

Early research data has shown that antibodies produced by prior infection or existing vaccines against the coronavirus were sufficient to protect against the new BA.2.86 variant, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday.

No so fast, the researches from Japan warn in a new study uploaded to bioXriv on Sep. 7, 2023, “Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant”:

The sera obtained from individuals vaccinated with 3rd-dose monovalent, 4th-dose monovalent, 4th-dose BA.1 bivalent, and 4th-dose BA.5 bivalent mRNA vaccines exhibited very little or no antiviral effects against BA.2.86. Moreover, the three monoclonal antibodies (Bebtelovimab, Sotrovimab and Tixagevimab), which worked against the parental BA.2, did not exhibit antiviral effects against BA.2.86. These results suggest that BA.2.86 is one of the most highly immune evasive variants ever.

Also, “UK reports nursing home COVID outbreak involving BA.2.86 variant” (University of Minnesota, 2023.09.08):

The HSA said BA.2.86 was detected at the nursing home in Norfolk after an unusually high number of people became ill during the last weeks of August. Positive samples were sent for genetic sequencing, which confirmed BA.2.86 in 28 of 43 samples. The attack rate was 86.6% among residents. Twelve staff members also tested positive.
Of 33 nursing home residents who tested positive, at least 29 had been vaccinated during the spring COVID booster campaign. All four of the residents who tested negative had received the shot in the spring.

As well, “ECDC details rising COVID-19 as more Asian nations report BA.2.86” (University of Minnesota, 2023.09.08).

And according to same researchers from Japan, EG.5.1 is not far behind of his younger brother, “Characterization of an EG.5.1 clinical isolate in vitro and in vivo” (2023.08.31):

…We also found that EG.5.1 is transmitted more efficiently between hamsters compared with XBB.1.5. In addition, unlike XBB.1.5, we detected EG.5.1 virus in the lungs of four of six exposed hamsters, suggesting that the virus tropism of EG.5.1 is different from that of XBB.1.5 after airborne transmission.
Finally, we assessed the neutralizing ability of plasma from convalescent individuals and found that the neutralizing activity against EG.5.1 was slightly, but significantly, lower than that against XBB.1.5 or XBB.1.9.2. This suggests that EG.5.1 effectively evades humoral immunity and that the amino acid differences in the S protein of EG.5.1 compared with that of XBB.1.5 or XBB.1.9.2 (i.e., Q52H, R158G, and F456L) alter the antigenicity of EG.5.1.
Our data suggest that the increased transmissibility and altered antigenicity of EG.5.1 may be driving its increasing prevalence over XBB.1.5 in the human population.

It seems like the prophesies of Geert Vanden Boschee finally come true in the second half of 2023.

Happy jabbing to those that are up to it! Do it for the vulnerable and Big Pharma! Obviously not for your own sake at this juncture. Quite the opposite.